Results from the DANISH Study (Danish Study to Assess the Efficacy of ICDs in Patients With Non-Ischemic Systolic Heat Failure on Mortality) suggest that for many patients with dilated cardiomyopathy (DCM), implantable cardioverter-defibrillators do not increase longevity. Accurate identification of patients who are more likely to die of an arrhythmia and less likely to die of other causes is required to ensure improvement in outcomes and wise use of resources. Until now, left ventricular ejection fraction has been used as a key criterion for selecting patients with DCM for an implantable cardioverter-defibrillator for primary prevention purposes. However, registry data suggest that many patients with DCM and an out-of-hospital cardiac arrest do not have a markedly reduced left ventricular ejection fraction. In addition, many patients with reduced left ventricular ejection fraction die of nonsudden causes of death. Methods to predict a higher or lower risk of sudden death include the detection of myocardial fibrosis (a substrate for ventricular arrhythmia), microvolt T-wave alternans (a marker of electrophysiological vulnerability), and genetic testing. Midwall fibrosis is identified by late gadolinium enhancement cardiovascular magnetic resonance imaging in ≈30% of patients and provides incremental value in addition to left ventricular ejection fraction for the prediction of sudden cardiac death events. Microvolt T-wave alternans represents another promising predictor, supported by large meta-analyses that have highlighted the negative predictive value of this test. However, neither of these strategies have been routinely adopted for risk stratification in clinical practice. More convincing data from randomized trials are required to inform the management of patients with these features. Understanding of the genetics of DCM and how specific mutations affect arrhythmic risk is also rapidly increasing. The finding of a mutation in lamin A/C, the cause of ≈6% of idiopathic DCM, commonly underpins more aggressive management because of the malignant nature of the associated phenotype. With the expansion of genetic sequencing, the identification of further high-risk mutations appears likely, leading to better-informed clinical decision making and providing insight into disease mechanisms. Over the next 5 to 10 years, we expect these techniques to be integrated into the existing algorithm to form a more sensitive, specific, and costeffective approach to the selection of patients with DCM for implantable cardioverter-defibrillator implantation.
D
ilated cardiomyopathy (DCM) is a disease of the myocardium characterized by a reduction in left ventricular (LV) systolic function and LV dilatation that cannot exclusively be explained by abnormal loading or ischemic injury. 1 It is one of the most common cardiomyopathies, with a predicted incidence of 1 in 400 in the United States.
2 Three-year treated mortality rates remain high at 12% to 20%, with death typically resulting from heart failure (HF) or ventricular arrhythmia manifesting as sudden cardiac death (SCD).
3-7 DCM accounts for a substantial proportion of SCD, especially among people of working age, with an annual incidence of 2% to 3%. 6, [8] [9] [10] SCD is unheralded in 40% to 50% of cases and occurs out of hospital in the majority of patients. 10, 11 Implantable cardioverter-defibrillators (ICDs) have the ability to promptly recognize and treat ventricular arrhythmias and thus form the cornerstone of SCD prevention. Patients with DCM compared with those with ischemic heart disease are typically younger with less comorbidity and therefore have a lower mortality risk from other causes. They therefore appear to be ideal candidates to benefit from ICD therapy.
Current guidelines recommend the use of ICDs for the primary prevention of SCD in patients with DCM, New York Heart Association (NYHA) class II to III HF, and a LV ejection fraction (LVEF) <35%. 12, 13 However, 4 individual randomized trials have failed to show a significant reduction in all-cause mortality with ICD therapy in patients with DCM and a LVEF <35%, and only 1 trial has demonstrated mortality benefit in patients with both ischemic and nonischemic etiologies. [5] [6] [7] A more precise risk stratification algorithm is therefore a major unmet need. In this review, we summarize the current evidence for primary prevention ICD implantation in patients with DCM and illustrate the need for improved risk stratification. [5] [6] [7] 14 We discuss strategies and techniques that we expect to be used to improve risk stratification over the next 5 to 10 years by providing more comprehensive disease phenotyping. We review techniques that may improve risk stratification, building from simple clinical variables to more complex imaging techniques and genetic analysis.
PRIMARY PREVENTION ICD TRIALS IN DCM: THE NEED TO IMPROVE THE SENSITIVITY AND SPECIFICITY OF THE CURRENT APPROACH
Five trials have investigated the effect of ICD implantation in patients with DCM without a history of cardiac arrest or hemodynamically unstable ventricular arrhythmia (Table 1) . [3] [4] [5] [6] [7] CAT (Cardiomyopathy Trial) and AMIOVIRT (Amiodarone Versus Implantable Cardioverter-Defibrillator) were terminated prematurely because of a low mortality rate and lack of statistical power.
3,4 SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) investigated the effect of primary-prevention ICD implantation in patients with ischemic cardiomyopathy or DCM with NYHA class II to III HF and an LVEF <35%. 5 ICD therapy was associated with a reduction in overall mortality across both etiologies Amio indicates amiodarone; AMIOVIRT, Amiodarone Versus Implantable Cardioverter-Defibrillator; C, optimal medical therapy arm; CAT, Cardiomyopathy Trial; CI, confidence interval; CRT, cardiac resynchronization therapy; DANISH, Danish Study to Assess the Efficacy of ICDs in Patients With Non-Ischemic Systolic Heart Failure on Mortality; DCM, dilated cardiomyopathy; DEFINITE, Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation; HR, hazard ratio; I, implantable cardioverter-defibrillator therapy arm; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; NSVT, nonsustained ventricular tachycardia; NT-proBNP, N-terminal-propeptide brain natriuretic peptide; NYHA, New York Heart Association; OMT, optimal medical therapy; PVC, premature ventricular complex; and SCD-HeFT, Sudden Cardiac Death in Heart Failure Trial. Overall mortality was <5%/y, and in the control group, only one third of the deaths were attributed to SCD. Notably, the percentage of patients treated with contemporary OMT was higher than in previous trials; 97% were prescribed angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and 92% were prescribed β-blockers. In addition, 58% of patients in both arms received cardiac resynchronization therapy, including 93% of those with left bundle-branch block and a QRS >150 milliseconds. Cardiac resynchronization therapy alone may reduce SCD risk by improving LV function and preventing bradycardia-triggered lethal arrhythmias. An updated meta-analysis, including data from DANISH, has demonstrated a 23% reduction in all-cause mortality with ICD therapy compared with OMT alone (HR, 0.77; 95% CI, 0.64-0.91). 16 Additional interpretation of the trials demonstrates the poor specificity of LVEF-based guidelines. In each of the trials, there was a low incidence of appropriate ICD therapies: 5.1% over 1 year in SCD-HeFT, 17.9% over 3 years in DEFINITE, and 11.5% over 5.6 years in DANISH. [5] [6] [7] This finding is partially explained by an improved prognosis for many with OMT. LV reverse remodeling occurs in up to 37% of patients treated with OMT, supporting the importance of postponing risk stratification until after a period of OMT. 17 In DEFINITE, of those with a follow-up LVEF, approximately half had an improvement in LVEF >5% associated with substantially reduced mortality. 18 Another explanation for the low incidence of appropriate therapies is a high residual incidence of death from competing causes; as the risk of nonsudden death increases, the chances of gaining benefit from ICD therapy diminish.
Conversely, it is clear that the sensitivity of LVEF for predicting SCD is poor. Registries of out-of-hospital cardiac arrests have demonstrated that the majority of such patients do not have severely reduced LVEF. 10, 11 In the Oregon and Maastricht registries, in those cases with premortem echocardiography, only 20% to 30% had a low enough LVEF to meet the criteria for an ICD.
10,11 DCM-specific registries have confirmed that although the overall risk of SCD may be higher in patients with severely reduced LVEF, the number with mild or moderate reductions in LVEF is greater and their risk remains significant. 19 Moreover, these patients are likely to have lower risks of death from competing causes and less likely to be limited by symptoms. The number of quality-adjusted life-years gained from successful ICD therapy may therefore be greater.
The risk of complications and the costs of ICD implantation are also important considerations. Although less common compared with 10 years ago, the incidence of inappropriate shocks is associated with morbidity and reduced quality of life. 6, 7, 20 Early procedurerelated complications occur in 4% of cases, whereas device-related infection complicates 4.9%. 7, 21 In addition to worsening outcomes, complications add costs to the considerable expenditure associated with ICDs. It has been estimated that if devices were implanted as recommended, an extra 850 000 patients in the United States would be offered ICD implantation, in addition to the 80 000 patients who currently receive them annually, at a total cost of $30 billion. 22 These issues highlight the wider importance of optimizing the selection of patients.
In conclusion, current research demonstrates the inadequacy of a risk-stratification algorithm based on LVEF and illustrates the importance of developing a more sensitive, specific, and cost-effective approach. We discuss other clinical and biomarker variables that may have a role in predicting the risk of nonsudden death and in the identification of those unlikely to benefit from ICD implantation and imaging and genetic techniques that detect those at high-risk of SCD ( Figure 1 ).
STAGE OF DISEASE, COMORBIDITIES, AND COMPETING RISKS FROM NONSUDDEN CAUSES OF DEATH
It has long been recognized that patients with advanced HF are unlikely to benefit from ICD therapy because of the high rates of death from nonarrhythmic causes. This is reflected in guidelines that do not recommend ICD implantation for patients with NYHA class IV symptoms, unless cardiac transplantation is planned, or for those with a life expectancy <1 year. 12, 13 The risk of death from nonsudden causes is especially relevant in older patients and in those with more comorbidities. In planned subgroup analysis of the DANISH trial, patients >68 years of age had a trend toward increased mortality with ICD implantation (HR, 1.19; 95% CI, 0.81-1.73; P=0. 38) , in contrast to patients <59 years of age who had a lower mortality with an ICD (HR, 0.51; 95% CI, 0.29-0.92; P=0.02). 7 In addition, a meta-analysis of trials of primary prevention ICDs in ischemic and nonischemic HF demonstrated the absence of survival benefit in patients with an estimated glomerular filtration rate of <60 mL·min . 23 This highlights the role that age and measures of kidney function may have in identifying patients who are unlikely to gain benefit from ICD implantation.
Risk scores such as the Seattle Heart Failure Model have been developed to predict prognosis in patients with HF, incorporating variables such as NYHA class and prescription of medical therapies with age and kidney function. 24 The Seattle model has been shown to be more accurate in the stratification of the risk of nonsudden death compared with SCD in populations with ischemic and nonischemic HF. 25 For example, patients with a score of 3 and 4 compared with those with a score of 0 have a relative risk of HF death of 38.4 and 87.6 and a relative risk of SCD of only 6.5 and 6.5, respectively. This highlights that although the risk of SCD rises with worsening HF, the rise in the risk of HF death is even greater, reducing the chances of gaining quality-adjusted life-years from ICD therapy. Although similar models have been developed for the prediction of SCD in HF populations and the wider general population, they are limited by an inability to reliably discriminate between the risk of SCD and nonsudden death and therefore have limited clinical utility. [26] [27] [28] There is growing interest in the use of circulating biomarkers of myocardial stress and fibrosis such as natriuretic peptides, troponin, galectin-3, and soluble ST2 to predict prognosis. However, these biomarkers generally reflect the severity of cardiac dysfunction rather the specific risk of SCD. They may be used to identify patients who are unlikely to benefit from ICD therapy because of a high risk of death resulting from the progression of HF. In prespecified subgroup analysis of DANISH, patients with a N-terminal pro-B-type natriuretic peptide >1177pg/mL randomized to ICD therapy had an all-cause mortality similar to that of those in the control arm (HR, 0.99; 95% CI, 0.73-1.36; P=0.96), whereas mortality was lower in those assigned to an ICD when N-terminal pro-B-type natriuretic peptide was <1177pg/mL (HR, 0.59; 95% CI, 0.38-0.91; P=0.02). 7 Similarly, Ahmad and colleagues 29 demonstrated a stronger association between N-terminal pro-B-type natriuretic peptide, galectin-3, and soluble ST2 and HF death compared with SCD in patients with ischemic and nonischemic HF. In summary, biomarkers, in combination with clinical variables and prognostic scores, offer the most potential for the identification Figure 1 . Flowchart of the potential techniques that may be used to improve risk stratification. Also shown are the main characteristics of the condition assessed by each technique and the interaction of these characteristics with the risk of either sudden cardiac death or nonsudden death. LGE-CMR indicates late gadolinium-enhanced cardiovascular magnetic resonance; MIBG, metaiodobenzylguanidine; MTWA, microvolt T-wave alternans; NYHA, New York Heart Association; SCD, sudden cardiac death; and SHFM, Seattle Heart Failure Model.
of patients with an excessively high risk of death resulting from competing causes who are thus unlikely to benefit from ICD therapy. The threshold at which the risk of death from competing causes outweighs the risk of SCD and the benefit from ICD therapy becomes unlikely is not clear.
MARKERS OF ELECTRIC INSTABILITY AND SCD RISK
Many studies have evaluated the ability of electric measurements to predict the risk of SCD in DCM. 30 These have included ECG findings such as QRS duration, QRS fragmentation, microvolt T-wave alternans (MTWA), left bundle-branch block, and late potentials on signal averaging; markers of autonomic tone, including baroreflex sensitivity, heart rate variability, and heart rate turbulence; and ventricular ectopy and nonsustained VT on monitoring or after programmed stimulation. The results of these, often small, studies have been inconsistent, and their combined utility is limited by the use of different end points. 30 A large meta-analysis combined 45 studies including 6088 patients with nonischemic DCM in an attempt to summarize existing data. 30 When available, arrhythmic end points, including SCD, ventricular arrhythmia, or appropriate ICD discharge, were used; all-cause mortality was used as an alternative when they were not available. Although interstudy reproducibility was poor for the majority of variables, the authors concluded that the most promising for the prediction of adverse events were QRS complex fragmentation (odds ratio [OR], 6.73; 95% CI, 3.85-11.76; P<0.001) and the presence of MTWA (OR, 4.66; 95% CI, 2.55-8.53; P<0.001). The ORs for the majority of the remaining parameters were between 1.5 and 3.0, suggesting lower predictive value (Table 2) .
Although the small number of studies limits the ability to interpret the predictive ability of QRS fragmentation, a large number of studies support the potential of MTWA, and a meta-analysis of patients with nonischemic DCM 31 has corroborated the findings of Goldberger and colleagues. 30 A study in a mixed ischemic and nonischemic population has suggested that the presence of MTWA may be a stronger predictor of arrhythmia when present in patients taking β-blockers (patients on β-blockers: HR, 5.39; 95% CI, 2.68-10.84; P<0.001; entire population: HR, 1.95; 95% CI, 1.29-2.96; P=0.002). 32 Others have emphasized the negative predictive value of a negative MTWA test 33 ; however, it should be noted that even a coin toss has a high negative predictive value when the event rate is low. 34 Hohnloser and Cohen 35 have proposed the use of MTWA testing to select patients with an LVEF <35% who are unlikely to benefit from ICD implantation, but this has not been validated.
ECHOCARDIOGRAPHY
Echocardiography is the first-line imaging investigation in the workup of patients with DCM. Use of echocardiography measurements to predict arrhythmic events is therefore an attractive concept. The ability of global longitudinal strain and mechanical dispersion, a measure of mechanical dyssynchrony, to predict sustained ventricular arrhythmia or SCD was investigated in 94 patients with nonischemic DCM over 22 months by Haugaa and colleagues. 36 They found that both measures independently predicted the major arrhythmic end point (per 1% increase in strain: HR, 1.26; 95% CI, 1.03-1.54; P=0.02; per 10-millisecond increase in mechanical dispersion: HR, 1.20; 95% CI, 1.03-1.40; P=0.02). They also demonstrated that both variables had larger areas under the curve on receiver-operating 37 Longitudinal strain was independently associated with the primary end-point of appropriate ICD therapy, albeit to a modest degree (per 1% increase: HR, 1.12; 95% CI, 1.01-1.20; P=0.032). Importantly, however, it appears unlikely that functional techniques such as strain measurement will provide adequate discrimination between the risk of SCD and death resulting from HF.
THE ROLE OF MYOCARDIAL FIBROSIS IN SCD RISK STRATIFICATION
One of the characteristic pathological features of DCM is the formation of myocardial fibrosis, a consequence of an increase in collagen formation in the extracellular matrix and myocyte cell death. 38 Histological studies have demonstrated 2 forms of fibrosis: replacement and interstitial fibrosis. 38 Replacement fibrosis describes discrete areas of myocardial scarring that develop as a result of myocyte cell death, whereas interstitial fibrosis is the result of expansion of the interstitium with accumulation of collagen in the absence of cell death (Figure 2) . 22 Fibrosis is the result of activation of the renin-angiotensin-aldosterone system and the β-adrenergic axis, which occurs as part of the HF syndrome. 39 Other environmental insults, implicated in the origin of DCM such as chemotherapy and viral myocarditis, play a role through the activation of inflammatory networks and the production of reactive oxygen species. 39 The result is the activation of myofibroblasts, the production of collagen, and myocyte cell death. 38, 39 Fibrosis is thought to provide a substrate for ventricular arrhythmia. An electric mapping study in patients with DCM demonstrated that only those with replacement fibrosis, identified by late gadolinium-enhanced A, Late gadolinium enhancement cardiovascular magnetic resonance image of a midventricular short-axis slice in a healthy control subject. B, Native T1 map of a midventricular short-axis slice in a healthy control with a mean myocardial T1 of 1240 milliseconds. C, Late gadolinium enhancement image of a midventricular short-axis slice in a patient with dilated cardiomyopathy (DCM) demonstrating linear midwall enhancement. D, Native T1 map of a midventricular short-axis slice in a patient with DCM with a mean myocardial T1 of 1375 milliseconds. Scans were performed on a 3-T Siemens Skyra (Erlangen, Germany). E, Microscopic examination of a sample taken from the septum of an explanted heart after transplantation demonstrating the presence of replacement fibrosis (blue arrow) and pericellular interstitial fibrosis (yellow arrow). cardiovascular magnetic resonance (LGE-CMR), had inducible VT or a history of sustained VT. 40 Moreover, in patients with inducible VT, the major component was mapped to the area of replacement fibrosis. Mapping studies have also linked the presence of fibrosis to fractionated electrograms, slowed conduction, and conduction block, which have been associated with VT and ventricular fibrillation (VF). 41, 42 The gray zone between areas of fibrosis and surviving myocardium is thought to act as the nidus for reentry wave fronts in patients with ischemic heart disease, and similar mechanisms may account for 80% of VT in DCM. 43 
CMR, REPLACEMENT MIDWALL FIBROSIS, AND OUTCOME PREDICTION
LGE-CMR imaging has demonstrated that replacement fibrosis occurs in ≈30% of patients with DCM. This frequently occurs in a linear midwall distribution and has been validated with histology ( Figure 2) . 44, 45 Multiple studies have demonstrated an association between midwall fibrosis (MWF) on LGE-CMR imaging and SCD events in patients with DCM (Table 3) . [44] [45] [46] [47] [48] [49] [50] [51] [52] The largest study followed up 472 patients with nonischemic DCM of all severities for a median of 5.3 years. 44 Similar to other studies, 30.0% of patients had MWF. 47 
; P<0.001).
A recent study performed exclusively in patients with nonischemic DCM and an LVEF >40% suggests that LGE-CMR imaging identifies patients with less severe LV impairment at high risk of SCD. 53 Those with MWF had significantly higher rates of SCD and aborted SCD (defined as an appropriate ICD shock, a nonfatal episode of VF, or VT causing hemodynamic compromise and requiring cardioversion) compared with those without (HR, 9.2; 95% CI, 3.9-21.8; P<0.0001), and this remained similar after adjustment for other prognostic variables (HR, 9.3; 95% CI, 3.9-22.3; P<0.0001). Importantly, the risk of death from competing causes in patients with MWF and mild or moderate reductions in LVEF was low. However, further studies are needed to establish whether patients with LVEF >35% and highrisk features benefit from ICD therapy. 54 Although promising, there are currently no data from randomized studies confirming that patients with MWF benefit from ICD implantation, and it remains unclear whether the addition of LGE to LVEF will sufficiently improve risk stratification or whether additional variables will be required. 55 Pending randomized studies, the presence or absence of MWF on LGE-CMR imaging may be used to aid decision making with regard to ICD implantation in borderline cases. Further work is required to investigate the linearity of the relationship between the extent of MWF and SCD events and whether there are reproducible amounts of MWF that reliably predict hard adverse arrhythmic events with the most accuracy.
THE ROLE OF INTERSTITIAL FIBROSIS AND THE POTENTIAL OF T1 MAPPING
Interstitial fibrosis is an almost universal finding in DCM. 38 Although less comprehensive than the work on replacement fibrosis, there is some evidence to suggest that interstitial fibrosis is involved in the maintenance of reentry circuits and in the generation of focal tachycardias. 56 Noninvasive measurement of interstitial fibrosis therefore offers potential for risk stratification.
39 T1 mapping is a CMR technique that quantifies the T1 relaxation time of each myocardial voxel. A T1 map can be constructed in which the signal intensity of each voxel corresponds to the T1 time ( Figure 2 ). If performed before and after administering gadolinium, an extracellular contrast, the myocardial extracellular volume (ECV) can be calculated by estimating the amount of contrast in the extracellular compartment relative to the blood pool.
57 Native (precontrast) T1 times and ECV fraction correlate with the degree of interstitial fibrosis in a range of diseases, including DCM. 57, 58 Aus dem Siepen and colleagues 58 demonstrated good correlation between ECV and the collagen volume fraction on myocardial biopsy in patients with varying severities of nonischemic DCM (r=0.85). Another study demonstrated strong correlation between ECV on pretransplantation CMR and collagen volume fraction on 96 posttransplantation tissue samples taken from 16 segments of 6 patients' explanted hearts (r=0.75). 59 In addition, the authors demonstrated significantly higher ECV values in myocardial segments free of LGE in patients before transplantation compared to ECV values in healthy control subjects (41.4±5.0% versus 25.5±2.6%; P<0.001). 59 This suggests that it may be possible to measure interstitial fibrosis noninvasively. Early work has investigated the predictive value of T1 mapping in risk prediction. However, further studies are required to clarify whether one measure is superior to the other. The crucial question is whether T1 mapping provides additional value to LGE, which already forms part of a routine scan.
An alternative approach is the use of biomarkers of collagen turnover as a surrogate for myocardial fibrosis. 62 A correlation between serum procollagen type I carboxyterminal peptide and fibrosis on myocardial biopsy has been reported in hypertensive patients, and an association between galectin-3 and MWF on LGE-CMR in patients with nonischemic DCM has been demonstrated. 63, 64 Current studies investigating collagen biomarkers are limited by small numbers of patients and outcome events; therefore, no conclusions can be drawn about their potential role in SCD risk assessment. 65 More research is required.
CARDIAC

123-METAIODOBENZYLGUANIDINE IMAGING
Autonomic dysfunction has long been associated with ventricular arrhythmogenesis. 66 Variable sympathetic activation of the myocardium results in heterogeneities in conduction velocities and refractory periods, creating a proarrhythmic environment. 67 Although not part of routine practice, it is possible to detect cardiac autonomic dysfunction with 123-metaiodobenzylguanidine scintigraphy. Parameters indicating autonomic dysfunction include elevated tracer washout rates, abnormal ratio of uptake between the heart and mediastinum, and large myocardial tracer defects.
Several studies have supported the ability of these parameters to predict SCD and adverse arrhythmic events in patients with DCM and broader HF populations (Table 4). [68] [69] [70] [71] [72] [73] Merlet and colleagues 68 performed a study evaluating exclusively patients with nonischemic DCM. In multivariable analysis, they found that radionuclide- 
P<0.05
ADMIRE-HF indicates AdreView Myocardial Imaging for Risk Evaluation in Heart Failure; CI, confidence interval; H:M -heart:mediastinum; HR, hazard ratio; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; SCD, sudden cardiac death; and SRS, summed rest score.
*Witnessed cardiac arrest, death within 1 hour after onset of symptoms, or unexpected, unwitnessed death in a patient known to have been well 24 hours previously.
†Sustained ventricular tachycardia, resuscitated cardiac arrest, appropriate ICD shock or antitachycardia pacing. ‡Appropriate ICD shock or antitachycardia pacing.
determined LVEF (P=0.02) and low heart:mediastinum (H:M) ratio (P<0.0001) predicted all-cause mortality, whereas low H:M ratio predicted SCD (P=0.0015). The ADMIRE-HF study (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) demonstrated that in patients with ischemic and nonischemic HF, an H:M ratio ≥1.6 was associated with a lower risk of adverse arrhythmic events (defined as spontaneous sustained VT, resuscitated cardiac arrest, or appropriate ICD therapy including ATP; 3.5% versus 10.4%; P<0.01) and a lower incidence of the primary composite end point, which included arrhythmic events, NYHA progression, and cardiovascular death (HR, 0.36; 95% CI, 0.17-0.75; P=0.006). 70 Survival modeling of patients without an ICD at enrollment demonstrated that the H:M ratio added incremental prognostic value and improved net reclassification, but it did not identify those who had improved survival with ICD implantation. 67, 74 A substudy of ADMIRE-HF assessed the value of summed rest score on single photon emission computed tomography, a marker of myocardial scar, in risk-stratifying 317 patients with nonischemic HF. 69 Overall, there were 22 arrhythmic events, defined as appropriate ICD therapy (ATP or shock), resuscitated cardiac arrest, and sustained VT, over a median of 17 months. On univariable analysis, an H:M ratio <1.6 and a summed rest score >8 were associated with the end point. Multivariable analysis performed in patients with an H:M ratio <1.6 demonstrated that a summed rest score of >8 was the only independent predictor of the end point.
These studies support the hypothesis linking autonomic dysfunction to increased rates of SCD. Further larger studies confirming the findings in patients with DCM and the measurements with the best sensitivity and specificity for the prediction of SCD are required.
UNRAVELING THE COMPLEX GENETIC FRAMEWORKS OF DCM AND SUDDEN DEATH The Genetic Basis of DCM
Over the last 20 years, as a result of advances in sequencing, the literature on the genetics of DCM has increased exponentially. Familial DCM is defined as idiopathic DCM in at least 2 closely related relatives and is thought to account for 25% to 50% of idiopathic DCM. 1 In familial DCM, a genetic cause is identified in 30% to 40% of cases with >100 single genes linked to the disease (Figure 3) . 75, 76 The majority of mutations occur in autosomal genes, with a small number of Xlinked and mitochondrial mutations identified. Most are unique to the family in which they were discovered and are called private mutations. 2 Inheritance has long been considered mendelian and therefore thought to be secondary to a single potent genetic mutation, with segregation in affected family members, crossing generations. However, cases with reduced penetrance, variable expressivity, and multiple mutations are not infrequent. Reduced and age-dependent penetrance and variable expressivity illustrate the importance of environmental modifiers such as viral triggers or excess alcohol consumption, which may unmask the phenotype ( Figure 3) . 2, [77] [78] [79] [80] [81] [82] [83] [84] [85] A study has demonstrated a similar incidence of genetic variants in women with peripartum cardiomyopathy compared with patients with idiopathic DCM, suggesting a shared genetic etiology across the spectrum of DCM, unmasked by different insults. 86 The diverse range of genes thought to cause DCM, encoding for a wide range of proteins with different functions, not only adds to the challenges of variant interpretation but also creates them in the search for new mutations. 3 The most common mutations occur in genes encoding sarcomeric proteins and in genes related to the nuclear envelope and the cytoskeleton. With the growth in sequencing, the identification of rare variants that contribute to the disease phenotype and carry adverse arrhythmic risk is becoming foreseeable. Considering that DCM is often diagnosed late and occasionally at postmortem, genetic screening enabling early diagnosis and risk stratification is attractive. We discuss here our understanding of the risk associated with specific mutations and work aimed at identifying genetic modifiers of risk.
DCM Genetics and SCD Risk
Despite advances, there are currently only specific instances when genetic results influence risk stratification. The most common circumstance is the identification of a pathogenic mutation in the lamin A/C (LMNA) gene, which encodes both the lamin A and C proteins, part of the nuclear envelope. More than 200 LMNA mutations have been associated with the development of DCM with variable involvement of skeletal muscle. 76 The cardiac phenotype is associated with premature conduction system disease and atrial and ventricular arrhythmia. The largest study on lamin cardiomyopathy to date followed up 94 patients with LMNA mutations over a median of 57 months. 77 Sixty patients had phenotypic evidence of disease at enrollment, and all those who reached 60 years of age developed the phenotype. Mortality in patients with a positive phenotype was 40% at 5 years, whereas 45% suffered SCD or aborted SCD. This confirmed LMNA cardiomyopathy to be a malignant and penetrant condition with worse outcomes compared with other forms of DCM. This has been replicated in other studies and supports the view that ICDs should be implanted earlier than current This figure demonstrates the acquired and genetic insults implicated in the pathogenesis of dilated cardiomyopathy (DCM) followed by the common genetic mutations associated with DCM (incidence of mutations in cases of idiopathic DCM followed by the protein encoded by the gene 2 ) and data on disease outcomes. Abs indicates antibodies; LVRR, left ventricular reverse remodeling; phaeo, phaeochromocytoma; and SCD indicates sudden cardiac death. guidelines recommend in these patients and in all those requiring pacemaker implantation. 77, 78 Truncating mutations of the titin (TTN) gene, which encodes the giant titin protein, are thought to be the most common causative mutations, occurring in 25% cases of familial DCM, 18% of sporadic cases, and <1% of controls. 87 Two molecules of titin span the length of the sarcomere and act to generate and regulate contractile force. 88 Titin has an important role in modulating responses to insults and loads, and truncating mutations appear to result in susceptibility to developing contractile impairment. 89 Herman and colleagues 79 studied 312 patients with DCM and demonstrated similar rates of adverse outcomes in patients with truncating mutations in TTN compared with those without. More recently, Jansweijer et al 80 demonstrated that patients with DCM with truncating variants in TTN had a milder phenotype of disease at baseline and higher rates of reverse remodeling compared with patients with LMNA mutations and those without a variant identified. This suggests that DCM related to TTN may be a more treatable form. Larger studies investigating SCD end points are required.
Studies in patients with other mutations have been smaller. Merlo and colleagues 81 studied 179 families with DCM and compared patients with rare sarcomeric gene variants with genotype-negative patients. Overall, 52 patients had rare variants in TTN (titin), MYH 6 (alpha-myosin heavy chain), MYH7 (beta-nyosin heavy chain), TNNT2 (troponin T), and MYBC (myosin binding protein C), and although these patients had a higher LVEF at baseline, after 50 years of age, rates of adverse outcomes, including ventricular arrhythmia, death, and cardiac transplantation, were higher. Other studies have suggested that mutations in TNNT2 may predispose to ventricular arrhythmias independently of structural changes and that this may be mediated through alterations in myocyte calcium sensitivity. 82, 90 A study has demonstrated reduced arrhythmic susceptibility in mice with TNNT2 mutations treated with a calcium desensitizer. 90 A founder mutation in the PLN gene, which encodes phospholamban, a protein with an important role in calcium homeostasis, has been associated with profound arrhythmic tendencies in patients with DCM and in those without structural phenotypes. 83 Van Rijsingen and colleagues 83 studied 403 carriers of a specific mutation in the PLN gene, 21% of whom met diagnostic criteria for DCM. Over 42 months, 19% had malignant ventricular arrhythmia defined as SCD, resuscitated cardiac arrest, or appropriate ICD intervention. In patients with an LVEF <45%, the incidence of ventricular arrhythmia rose to 39%. These studies suggest that mutations in genes controlling calcium handling, also known to cause DCM, may influence arrhythmic risk independently of structural changes. This provides an opportunity for the development of therapeutics targeting specific mechanisms of arrhythmogenesis.
Another study in 436 men with DCM identified dystrophin variants in 34. 84 Over 60 months, patients with dystrophin mutations had high rates of HF events, with 23% undergoing transplantation and 26% dying of HF. Conversely, however, they demonstrated low incidences of major arrhythmic events with no patients suffering SCD or life-threatening ventricular arrhythmia. Although small, this study suggests that patients with dystrophin variants should be streamlined to advanced HF therapies rather than ICD implantation.
Recently, truncating mutations in FLNC, a gene that encodes filamin, a protein that attaches membrane proteins to the cytoskeleton, have been associated with an arrhythmogenic phenotype, similar to that observed with desmin mutations. 85 In 2877 patients with inherited cardiovascular disease, truncating mutations in FLNC were identified in 28 probands and 54 relatives. 85 Overall, 97% of carriers >40 years of age had phenotypic evidence of the disease characterized by LV dilatation, reduced LVEF, and myocardial fibrosis. Twelve carriers suffered SCD during the study, conducted over 3.5 years, and there was a history of SCD in 28 relatives of carriers without genetic data. Altogether, 21 of 28 evaluated families had a history of SCD. This suggests that truncating mutations in FLNC are associated with a high incidence of SCD.
In conclusion, large longitudinal studies investigating specific SCD-focused end points in patients with DCM and specific rare variants are required to better inform decision making. Currently, it appears that in addition to carriers of LMNA mutations, carriers of a specific PLN mutation or truncating FLNC mutations should be stratified at higher risk of SCD.
Genome-Wide Association Studies: DCM and SCD Risk
Given the variable penetrance and expressivity seen in DCM, the importance of genetic (and environmental) modifiers has widely been accepted. Genetic susceptibility to SCD has also been recognized, with the incidence of VF in patients having an acute myocardial infarction strongly associated with a family history of SCD, independently of other traditional ischemic heart disease variables. 91 Based on these observations, genome-wide association studies have attempted to identify novel susceptibility loci that modify an individual's risk of developing DCM and suffering SCD. These types of studies mostly identify single-nucleotide polymorphisms in noncoding DNA that are thought to affect gene expression.
A small number of loci associated with the development of DCM have been reported. 92 These include a single-nucleotide polymorphism within the major histocompatibility complex on chromosome 6, which has also been linked to inflammatory diseases such as pso-riasis. 92 The authors use this to support the hypothesis that a genetically driven inflammatory mechanism underlies the disease in some patients.
Genome-wide association studies performed in large populations of patients with SCD have identified several potential loci that are associated with an individual's risk, albeit to a modest extent. [93] [94] [95] Perhaps the most promising are those associated with the BAZ2B (Bromodomain adjacent to zinc finger domain 2B) and CXADR (coxsackie virus and adenovirus receptor) genes, the latter of which has been linked to the development of DCM and myocarditis. 93, 95 Other groups have identified single-nucleotide polymorphisms that modify electric parameters such as QRS and QT intervals, known as endophenotypes, which are known to influence arrhythmic risk. 96 Genetic variants known to modify endophenotypes have been linked to increased arrhythmic risk in other diseases and may have similar effects in DCM. 96 In summary, the scope of genetics to identify common variants that may modify SCD risk is great. However, advanced work in coronary disease has emphasized the small incremental value of each variant in isolation and the possible need for the effects of even hundreds of variants to be combined into a model to provide a clinically useful estimation of risk in a heterogeneous disease.
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CONCLUSIONS
Existing guidelines lack sensitivity and specificity for the selection of patients with DCM for primary-prevention ICD implantation. These require refinement to produce a more personalized and precise approach, with the aim of improving outcomes and cost-efficiency. Incorporating methods that identify patients at particularly high risk of death from competing causes, who are unlikely to benefit from ICD therapy, will form an important part of this process. There is growing evidence that characteristics other than LVEF may be used to identify those at increased risk of SCD. Considering the multifactorial basis of ventricular arrhythmogenesis in DCM, it appears likely that an algorithm including multiple tests that detect different pathophysiological processes involved in arrhythmia generation may be required.
LGE-CMR imaging is a routinely used technique in the investigation of DCM, and MTWA analysis is an inexpensive additional test that is relatively simple to perform. Observational data support the ability of these techniques to identify those at high risk of SCD. Nuclear imaging to detect autonomic dysfunction is another promising approach; however, the use of this technique in current practice is limited. Although a great deal of work is needed to integrate genetic risk prediction into clinical practice, we believe that the identification of high-risk rare variants, in addition to LMNA, will play an increasing role.
Multicenter, prospective registries incorporating CMR imaging, genetic, biomarker, and electrophysiological data in unselected DCM cohorts should be the next step in the pursuit of improved risk stratification, with the aim of creating a multivariable risk score that can accurately discriminate between the risk of SCD and nonsudden death. Predicted annual risks of these events at which patients are most likely to gain cost-effective benefit from ICD therapy may be confirmed, taking into account preexisting clinical trial data. This should be followed by randomized trials investigating the effects of interventions, including ICD implantation, in patients deemed to be at high risk of SCD and without an excessive risk of death from competing causes. 
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